ihodes

7 ms·

31.
by ihodes 7y ago
I'm curious if anyone here has compared Postgraphile to Hasura? My personal difficulty in implementing these is that there aren't good source control and code organization tools for SQL and managing rollbacks and rollforwards in a
32.
by ihodes 7y ago
As an anecdote, the major consulting firms (McKinsey, BCG, Bain), all provide constructive interview feedback after interviews. They do this regardless of if the candidate is moving on to the next level of not. It's strange that other
33.
by ihodes 7y ago
Is there something like this that's currently developed for Safari?
34.
by ihodes 7y ago
This depends on how the eggs are processed prior to you purchasing them, so beware. Cf. https://www.npr.org/sections/thesalt/2014/09/11/336330502/wh...
35.
by ihodes 7y ago
They do that, or contract with companies (like PBMs) to do so. That's been the way this works forever. Asymptotically no one pays the ~$40k+/mo list price.
36.
by ihodes 7y ago
That's really awful; I'm so sorry you both had to go through that. Would you mind sharing more information about how you found that list (esp for a given zip), and how you think they tied that information to an address? My email i
37.
by ihodes 8y ago
Might be of interest to you https://sloanreview.mit.edu/article/when-smart-goals-are-not...
38.
by ihodes 8y ago
Check out Kent Smetters if you're curious.
39.
by ihodes 8y ago
No, they explicitly made this a conditional handout this year, which is very much a termination of the original plan. UBI researchers have generally considered this a failure already (not to mention that many economists think UBI cannot wor
40.
Universal Basic Income Is Not Feasible(knowledge.wharton.upenn.edu)
59 points by ihodes 8y ago|103 comments
41.
by ihodes 8y ago
I believe it was supposed to run for two years. They ended it a year early. (First source that pops up: https://www.cnbc.com/2017/01/03/finland-experiments-universa... )
42.
by ihodes 8y ago
Thank you!
43.
by ihodes 8y ago
I'm unable to see that in your profile (looks blank to me). Do you mind updating it?
44.
by ihodes 8y ago
I'm curious to learn more about your clinic. Mind sharing any information?
45.
by ihodes 9y ago
The size comparison is a bit off; Manhattan is about half the size of SF ( https://www.comparea.org/r2552485+r111968 ). Of course, NYC is over 6x the size of SF ( https://www.comparea.org/r175905+r111968 ).
46.
by ihodes 9y ago
Also seems like a useful captive waypoint to monitor MAC addresses & movement across a city.
47.
by ihodes 9y ago
There are studies showing that some generics don't perform as well as the brand name. Different formulations of the same drug (e.g. extended release medications, different sized particles in inhalers, etc) can have vastly different eff
48.
by ihodes 9y ago
This is a more in-depth source for the same story: https://arstechnica.com/security/2017/04/brickerbot-the-perm...
49.
by ihodes 9y ago
What does the lack of multi core keep you from doing?
50.
by ihodes 10y ago
For those not in the field, it's worth noting that a good deal of research is disseminated prior to publishing (or while "in press"/waiting to be published) via conferences or word of mouth.
51.
by ihodes 10y ago
In emacs, `C-u M-| cmd <enter>` does this.
52.
by ihodes 10y ago
I have definitely have shared that sentiment. However, Apache didn't create this project; it's from Cloudera originally, and they've got a pretty good track record. In this case, Kudu is more of a database/store on top o
53.
by ihodes 10y ago
Took a few notes when reading the paper[1], expanded some acronyms as well. Definitely a nice result, and an interesting paper. * Steve Rosenberg's a respected expert in the field * Adoptive T cell therapy (ACT) of TIL (tumor-infiltrat
54.
by ihodes 10y ago
I haven't read a ton of CRISPR/CAS papers, but I have read the seminal ones, and didn't see that. Mutations in unmodified cells are completely expected, of course, but not mutations in line with where CRISPR is being targeted
55.
by ihodes 10y ago
It's certainly the former; CRISPR is used to mess with a gene, not kill a population of cells. This isn't what the trial is looking to validate.
56.
by ihodes 10y ago
Startups working on this (with credible founders, i.e. inventors of CRISPR) include Editas Medicine, Caribous Biosciences, and CRISPRx. Look out for Doudna, Qi, Charpentier, Elledge, and Church. Also see J. Listgarten for computation approa
57.
by ihodes 10y ago
Your questions are very good, and I answer them below briefly in the interest of expediency, not to be rude. 1. Some knowledge is shared in journals; most knowledge isn't published until years after it's established. Much is never
58.
by ihodes 10y ago
Hammer Lab | New York, NY (NYC) | Full-time, onsite We’re a team of software developers and data scientists working to understand and improve how the immune system battles cancer. We're looking for (1) a senior machine learning special
59.
by ihodes 10y ago
Feel free to email me if you're interested (even if you don't feel as though you're an ML expert)!
60.
by ihodes 10y ago
(Nearly) all our work (github.com/hammerlab) is OSS. We're hiring experts in ML if you're interested in working on big genomic data in the field of cancer immunotherapy. We're a lab (academic not-for-profit, part of Moun

More ›